POLYMED Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
Poly Medicure reported strong Q2/H1 FY27 results with standalone revenue up 17% YoY in Q2 and consolidated revenue up 31% (organic +14%). Gross margin expanded 111 bps YoY to 70.1% standalone, driven by proactive inventory management and price hikes. Management reaffirmed revenue guidance (INR2,300-2,400 cr consolidated) and raised standalone EBITDA margin guidance to 26-27.5%. Key headwinds include West Asia geopolitical issues impacting ROW markets (-7% in Q2), Chinese dumping in dialysis, and PendraCare EBITDA losses due to Middle East exposure. Key tailwinds include Europe recovery (~40% organic growth), India-UK FTA opportunities, DGHS single-use notification, and 30 new product registrations. Capex guidance maintained at INR200-225 cr for FY27.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong H1/Q2 performance with revenue up 17% and 31% consolidated, gross margin expansion, reaffirmed guidance, and strategic progress in Brazil, UK, and new product launches. Tone was confident and forward-looking.
- Q&A Session: Neutral — Analysts probed on regional weaknesses (ROW down 7%, Citieffe Italy tender delays, PendraCare losses), margin sustainability, and subsidiary recovery timelines. Management responses were detailed but acknowledged ongoing headwinds and uncertainty, particularly around Middle East logistics and margin
Revenue Growth Drivers
- Strong domestic growth across all verticals (infusion therapy, blood management, newer verticals)
- Europe business recovery with ~40% organic growth in Q2 driven by new customer additions (28-29 in H1) and deeper clinical engagement
- New customer additions (30 in six months) and cross-selling
Growth vs Margin Focus
Management reaffirmed revenue guidance while increasing standalone EBITDA margin guidance from 25-27% to 26-27.5%, demonstrating balanced focus. Targeting revenue doubling by FY30 while improving consolidated EBITDA margins.
About Poly Medicure Limited
Poly Medicure Limited (POLYMED) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.